- Thursday, July 30, 2026 @ 12:00 am
Volv Global has been selected as a finalist in the 2026 Fierce AI Innovation Awards, in the category AI Innovation in Real-World Evidence & Data Analytics.
The submission recognized in this category covers population-scale AI for real-world evidence generation and clinical trial enrichment across rare and difficult-to-diagnose diseases.
The recognition reflects years of work to find people living with rare and difficult-to-diagnose diseases whom the current system has missed. This includes people with AATD who have been told they have asthma, people with Fabry disease whose diagnosis never came, and people whose path to treatment has been measured in years—sometimes decades—longer than it should have been. With the right data and the right methodology, that gap can close.
Being selected as a finalist alongside organizations of the caliber of Flatiron Health, Verantos, and Rune Labs is a genuine honor and reflects the trust of the clinical and pharmaceutical partners whose collaboration has produced tangible results while strengthening the evidence at every step.
Winners will be announced on September 2
